# EDGAR Filing Document

**Accession Number:** 0001817229
**File Stem:** 0001193125-26-130452
**Filing Date:** 2026-3
**Character Count:** 26683
**Document Hash:** 237dc69dcfcc7ee636c789bf27face93
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-130452.hdr.sgml**: 20260330

**ACCESSION NUMBER**: 0001193125-26-130452

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 18

**FILED AS OF DATE**: 20260330

**DATE AS OF CHANGE**: 20260330

**EFFECTIVENESS DATE**: 20260330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vor Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001817229
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811591163
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294726
- **FILM NUMBER:** 26810046

**BUSINESS ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-655-6580

**MAIL ADDRESS:**
- **STREET 1:** 500 BOYLSTON STREET
- **STREET 2:** SUITE 1350
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

![gfx101492977_0.gif](gfx101492977_0.gif)

As filed with the U.S. Securities and Exchange Commission on March 30, 2026 <br> <u>Registration No. 333-</u>

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

------

**Vor Biopharma Inc.**

(Exact name of Registrant as specified in its charter)

------

---

| | |
|:---|:---|
| **Delaware** | **81-1591163** |
| (State or other jurisdiction of<br>Incorporation or organization) | (I.R.S. Employer<br>Identification No.) |
| **500 Boylston Street**<br>**Suite 1350**<br>**Boston, Massachusetts** | **02140** |
| (Address of principal executive offices) | (Zip code) |

---

**Amended and Restated 2021 Equity Incentive Plan**

**2021 Employee Stock Purchase Plan**

(Full titles of the plans)

------

**Jean-Paul Kress, M.D.**

**President and Chief Executive Officer**

**Vor Biopharma Inc.**

**500 Boylston Street**

**Suite 1350**

**Boston, Massachusetts 02116**

**(617) 655-6580**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

***Copies to:***

**Divakar Gupta**

**Madison A. Jones**

**Cooley LLP**

**55 Hudson Yards**

**New York, New York 10001-2157**

**(212) 479-6000**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

# EXPLANATORY NOTE
Pursuant to General Instruction E of Form S-8, this Registration Statement on Form S-8 (the "***Registration Statement***") is being filed for the purpose of registering an additional 1,638,807 shares of common stock, $0.0001 par value per share (the "***Common Stock***"), of Vor Biopharma Inc. (the "***Registrant***"), consisting of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•1,548,807 shares of Common Stock issuable pursuant to the Registrant's Amended and Restated 2021 Equity Incentive Plan (the "***2021 EIP***"), pursuant to the provisions of the 2021 EIP providing for an automatic increase in the number of shares reserved and available for issuance under the 2021 EIP on January 1, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•90,000 shares of Common Stock issuable pursuant to the Registrant's 2021 Employee Stock Purchase Plan (the "***2021 ESPP***"), pursuant to the provisions of the 2021 ESPP providing for an automatic increase in the number of shares reserved and available for issuance under the 2021 ESPP on January 1, 2026.

In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

# PART II

## ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** The contents of the Registrant's Registration Statements on Form S-8, filed with the Commission on February 9, 2021 (File No. 333-252908), March 14, 2022 (File No. 333-263540), March 23, 2023 (File No. 333-270789), March 21, 2024 (File No. 333-278117), March 20, 2025 (File No. 333-285971), and September 24, 2025 (File No. 333-290491);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026 (File No. 001-39979);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** The Registrant's Current Report on Form 8-K filed with the Commission on January 2, 2026 (File No. 001-39979) (to the extent the information in such reports is filed and not furnished); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** The description of the Registrant's Common Stock, which is contained in Exhibit 4.3 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 30, 2026 (File No. 001-39979), including any amendment or report filed for the purpose of updating such description.

All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

## ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL
As of the date of the date hereof, GC&H Investments, LLC and GC&H Investments, a California partnership, which are entities beneficially owned by current and former partners and associates of Cooley LLP, counsel to the Registrant, beneficially hold an aggregate of 35,350 shares of the Registrant's common stock.

## ITEM 8. EXHIBITS

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Exhibit<br>Number** | &nbsp;&nbsp;**Description** | &nbsp;&nbsp;**Schedule<br>Form** | &nbsp;&nbsp;**File<br>Number** | &nbsp;&nbsp;**Exhibit** | &nbsp;&nbsp;**Filing Date** |
| &nbsp;&nbsp;4.1 | &nbsp;&nbsp;[<u>Amended and Restated Certificate of Incorporation of the Registrant.</u>](https://www.sec.gov/Archives/edgar/data/1817229/000119312521034387/d117998dex31.htm) | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-39979 | &nbsp;&nbsp;3.1 | &nbsp;&nbsp;February 9, 2021 |
| &nbsp;&nbsp;4.2 | &nbsp;&nbsp;[<u>Certificate of Amendment of Amended and Restated Certificate of Incorporation.</u>](https://www.sec.gov/Archives/edgar/data/1817229/000119312525125833/d95113dex31.htm) | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-39979 | &nbsp;&nbsp;3.1 | &nbsp;&nbsp;May 23, 2025 |
| &nbsp;&nbsp;4.3 | &nbsp;&nbsp;[<u>Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Registrant.</u>](https://www.sec.gov/Archives/edgar/data/1817229/000119312525205553/d945826dex31.htm) | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-39979 | &nbsp;&nbsp;3.1 | &nbsp;&nbsp;September 17, 2025 |
| &nbsp;&nbsp;4.4 | &nbsp;&nbsp;[<u>Amended and Restated Bylaws of the Registrant.</u>](https://www.sec.gov/Archives/edgar/data/1817229/000119312521034387/d117998dex32.htm) | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-39979 | &nbsp;&nbsp;3.2 | &nbsp;&nbsp;February 9, 2021 |
| &nbsp;&nbsp;4.5 | &nbsp;&nbsp;[<u>Form of Common Stock Certificate of the Registrant.</u>](https://www.sec.gov/Archives/edgar/data/1817229/000119312521023537/d942530dex41.htm) | &nbsp;&nbsp;S-1/A | &nbsp;&nbsp;333-252175 | &nbsp;&nbsp;4.1 | &nbsp;&nbsp;February 1, 2021 |
| &nbsp;&nbsp;5.1\* | &nbsp;&nbsp;[<u>Opinion of Cooley LLP.</u>](vor-ex5_1.htm) |  |  |  |  |
| &nbsp;&nbsp;23.1\* | &nbsp;&nbsp;[<u>Consent of Cooley LLP (included in Exhibit 5.1).</u>](vor-ex5_1.htm) |  |  |  |  |
| &nbsp;&nbsp;23.2\* | &nbsp;&nbsp;[<u>Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.</u>](vor-ex23_2.htm) |  |  |  |  |
| &nbsp;&nbsp;24.1\* | &nbsp;&nbsp;[<u>Power of Attorney (included on the signature page of this registration statement).</u>](#power_of_attorney) |  |  |  |  |
| &nbsp;&nbsp;99.1 | &nbsp;&nbsp;[<u>2021 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement.</u>](https://www.sec.gov/Archives/edgar/data/1817229/000119312521023537/d942530dex106.htm) | &nbsp;&nbsp;S-1/A | &nbsp;&nbsp;333-252175 | &nbsp;&nbsp;10.6 | &nbsp;&nbsp;February 1, 2021 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.2 | &nbsp;&nbsp;[<u>Amended and Restated 2021 Equity Incentive Plan.</u>](https://www.sec.gov/Archives/edgar/data/1817229/000119312525189169/d24419dex101.htm) | &nbsp;&nbsp;8-K | &nbsp;&nbsp;001-39979 | &nbsp;&nbsp;10.1 | &nbsp;&nbsp;August 27, 2025 |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Exhibit<br>Number** | &nbsp;&nbsp;**Description** | &nbsp;&nbsp;**Schedule<br>Form** | &nbsp;&nbsp;**File<br>Number** | &nbsp;&nbsp;**Exhibit** | &nbsp;&nbsp;**Filing Date** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;99.3 | &nbsp;&nbsp;[<u>2021 Employee Stock Purchase Plan.</u>](https://www.sec.gov/Archives/edgar/data/1817229/000119312521023537/d942530dex107.htm) | &nbsp;&nbsp;S-1/A | &nbsp;&nbsp;333-252175 | &nbsp;&nbsp;10.7 | &nbsp;&nbsp;February 1, 2021 |
| &nbsp;&nbsp;107\* | &nbsp;&nbsp;[<u>Filing Fee Table.</u>](vor_exfilingfees.htm) |  |  |  |  |

---

------

\* Filed herewith

------

# SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on March 30, 2026.

**VOR BIOPHARMA INC.**

By: <u>/s/ Jean-Paul Kress</u> 

Jean-Paul Kress, M.D.

President, Chief Executive Officer and Chairman of the Board

# POWER OF ATTORNEY
**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below constitutes and appoints Jean-Paul Kress and Sandesh Mahatme, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Jean-Paul Kress<br>Jean-Paul Kress, M.D. | President, Chief Executive Officer and Chairman <br>of the Board <br>(*Principal Executive Officer*) | March 30, 2026 |
| /s/ Sandesh Mahatme<br>Sandesh Mahatme | Chief Financial Officer<br>(*Principal Financial Officer and Principal Accounting Officer*) | March 30, 2026 |
| /s/ Daniella Beckman<br>Daniella Beckman | Director | March 30, 2026 |
| /s/ Alexander Cumbo<br>Alexander Cumbo | Director | March 30, 2026 |
| /s/ Michel Detheux<br>Michel Detheux | Director | March 30, 2026 |
| /s/ Erez Kalir<br>Erez Kalir | Director | March 30, 2026 |
| /s/ Wouter Joustra<br>Wouter Joustra | Director | March 30, 2026 |
| /s/ Andrew Levin<br>Andrew Levin | Director | March 30, 2026 |
| /s/ Fouad Namouni<br>Fouad Namouni, M.D. | Director | March 30, 2026 |

---

------

## Exhibit 5.1

![gfx239642899_0.jpg](gfx239642899_0.jpg)

Cooley LLP 1299 Pennsylvania Avenue NW Suite 700 Washington, DC 20004-2400<br>t: +1 202 842 7800 f: +1 202 842 7899 cooley.com

![img239642899_0.jpg](img239642899_0.jpg)

Madison A. Jones

T: +1 202 728 7087

madison.jones@cooley.com

March 30, 2026

Vor Biopharma Inc.<br>500 Boylston Street, Suite 1350<br>Boston, MA 02116

Ladies and Gentlemen:

We have acted as counsel to Vor Biopharma Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a registration statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering of up to 1,638,807 shares (the "***Shares***") of the Company's common stock, par value $0.0001 per share (the "***Common Stock***"), consisting of (i) 1,548,807 shares of Common Stock issuable pursuant to the Company's Amended and Restated 2021 Equity Incentive Plan (the "***2021 Plan***") and (ii) 90,000 shares of Common Stock issuable pursuant to the Company's 2021 Employee Stock Purchase Plan (together with the 2021 Plan, the "***Plans***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectuses, (b) the Company's certificate of incorporation and bylaws, each as currently in effect, (c) the Plans and (d) such records, documents, opinions, certificates, memoranda, and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon and subject to the assumptions, exceptions, limitations and qualifications set forth herein, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and the related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

Our opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. Our opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

------

![gfx239642899_1.jpg](gfx239642899_1.jpg)

![img239642899_1.jpg](img239642899_1.jpg)![gfx239642899_0.jpg](gfx239642899_0.jpg)

Cooley LLP 1299 Pennsylvania Avenue NW Suite 700 Washington, DC 20004-2400<br>t: +1 202 842 7800 f: +1 202 842 7899 cooley.com

Vor Biopharma Inc.March 30, 2026<br>Page 2

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

Cooley LLP

---

| | |
|:---|:---|
| By: | /s/ Madison A. Jones |
|  | Madison A. Jones |

---

------

## Exhibit 23.2

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Amended and Restated 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan of Vor Biopharma Inc. of our report dated March 30, 2026, with respect to the consolidated financial statements of Vor Biopharma Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 30, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107**

**Calculation of** Filing Fee **Tables**

**Form** S-8

Vor Biopharma Inc.

**Table 1: Newly Registered and Carry Forward Securities  Not Applicable**

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Security Type** | **Security Class Title** | **Fee Calculation or Carry Forward Rule** | **Amount Registered** | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** | **Carry Forward Form Type** | **Carry Forward File Number** | **Carry Forward Initial Effective Date** | **Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward** |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the Amended and Restated 2021 Equity Incentive Plan | 457(a) | 1548807 | 12.29 | 19034838 | 0.0001381 | 2628.71 |  |  |  |  |
| Fees to be Paid | 2 | Equity | Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the 2021 Employee Stock Purchase Plan | 457(a) | 90000 | 10.45 | 940500 | 0.0001381 | 129.88 |  |  |  |  |
| Fees Previously Paid |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $19975338 |  | $2758.59 |  |  |  |  |
|  |  |  | Total Fees Previously Paid: | Total Fees Previously Paid: | Total Fees Previously Paid: |  |  |  | $0.00 |  |  |  |  |
|  |  |  | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  |  | $0.00 |  |  |  |  |
|  |  |  | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  |  | $2758.59 |  |  |  |  |

---

------

**Offering Notes**

1The amount registered represents shares of common stock of Vor Biopharma Inc. (the "Registrant") that were added to the shares reserved for future issuance under the Registrant's Amended and Restated 2021 Equity Incentive Plan (the "2021 EIP") on January 1, 2026 pursuant to a provision contained in the 2021 EIP pursuant to which the number of shares reserved for issuance under the 2021 EIP will automatically increase on January 1 of each year for a period of ten years commencing on January 1, 2026 and ending on (and including) January 1, 2035, in an amount equal to four percent (4%) of the total number of shares of the Registrant's common stock outstanding on December 31 of the preceding year; provided, however, that the Registrant's board of directors may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares. Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the 2021 EIP by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant's common stock. The proposed maximum offering price per unit is estimated solely for the purpose of calculating the proposed maximum aggregate offering price and the registration fee in accordance with Rules 457(c) and (h) under the Securities Act, based on the average of the high and low prices of the Registrant's common stock as reported in the consolidated reporting system of The Nasdaq Global Select Market on March 24, 2026, which was $12.29.

2The amount registered represents shares of the Registrant's common stock that were added to the shares reserved for future issuance under the Registrant's 2021 Employee Stock Purchase Plan (the "2021 ESPP") on January 1, 2026 pursuant to a provision contained in the 2021 ESPP pursuant to which the number of shares reserved for issuance under the 2021 ESPP will automatically increase on January 1st of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to the lesser of (i) one percent (1%) of the total number of shares of the Registrant's common stock outstanding on December 31st of the preceding year and (ii) 90,000 shares of common stock; provided, however, that the Registrant's board of directors may act prior to January 1st of a given year to provide that the increase for such year will be a lesser number of shares. Pursuant to Rule 416(a) promulgated under the Securities Act, this Registration Statement shall also cover any additional shares of the Registrant's common stock that become issuable under the 2021 ESPP by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's common stock. The proposed maximum aggregate offering price per unit is estimated solely for the purpose of calculating the proposed maximum aggregate offering price and the registration fee in accordance with Rules 457(c) and (h) under the Securities Act, based on the average of the high and low prices of the Registrant's common stock as reported in the consolidated reporting system of The Nasdaq Global Select Market on March 24, 2026, which was $12.29, multiplied by 85%, which is the percentage of the price per share applicable to purchases under the 2021 ESPP.

------

**Table 2: Fee Offset Claims and Sources  Not Applicable**

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Registrant or Filer Name** | **Form or Filing Type** | **File Number** | **Initial Filing Date** | **Filing Date** | **Fee Offset Claimed** | **Security Type Associated with Fee Offset Claimed** | **Security Title Associated with Fee Offset Claimed** | **Unsold Securities Associated with Fee Offset Claimed** | **Unsold Aggregate Offering Amount Associated with Fee Offset Claimed** | **Fee Paid with Fee Offset Source** |
| **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Fee Offset Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** | **Rules 457(p)** |
| Fee Offset Claims | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Fee Offset Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

---

------